The in vitro activity of the new macrolide antibiotic roxithromycin (RU 28965) was compared with the activities of five other orally absorbable antimicrobial agents against 100 clinical isolates of Haemophilus influenzae. Roxithromycin MICs were generally twofold to fourfold higher than those of erythromycin; the MIC for 90% of the strains for roxithromycin was 8 ,ug/ml.
Erythromycin is a macrolide antibiotic which is useful for therapy of infections due to strains of Legionella, Mycoplasma, Chlamydia, and Campylobacter, as well as for certain respiratory tract infections in penicillin-allergic patients. Roxithromycin (formerly RU 28965) is a new ether oxime derivative of erythromycin (4) 
